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Pathogenic IgA in IgA 
nephropathy: still the blind men 
and the elephant?
KN Lai1
IgA nephropathy (IgAN), the most common glomerulonephritis 
worldwide, remains an important cause of end-stage renal failure. The 
pathology is characterized by mesangial deposition of IgA. The disease 
is now recognized as arising from anomalies of the IgA molecule and the 
kidneys are innocent bystanders. The immunochemical nature of the 
IgA molecule and its mesangial uptake command a pivotal role in the 
pathogenesis of IgAN.
Kidney International (2006) 69, 1102–1103. doi:10.1038/sj.ki.5000205
Th e hallmark of IgA nephropathy (IgAN) 
is the mesangial immunoglobulin A 
(IgA) deposit, in which IgA is the domi-
nant or codominant immunoglobulin. 
Early mesangial IgA deposition that may 
lead to subsequent recurrence of IgAN 
occurs in renal allograft s, whereas a kid-
ney from an IgAN patient transplanted 
to a recipient without IgAN undergoes 
spontaneous recovery. Th us, IgAN is now 
recognized as secondary to anomalies of 
the IgA molecule, in which the kidneys 
are innocent bystanders. The human 
IgA immune system exists in two com-
partments: the mucosa-associated lym-
phoid tissue, and the bone marrow and 
plasma. Th e IgA molecule is a tetramer 
with two identical light chains, κ and λ, 
and two heavy chains, α1 and α2. λ-IgA 
has a restricted anionic range in IgAN 
as opposed to the broad range of normal 
IgA molecules. λ-IgA is highly anionic, 
whereas κ-IgA is highly cationic. In con-
trast to other immunoglobulins, human 
IgA displays unique heterogeneity in its 
molecular forms, each with a character-
istic distribution in various body fl uids. 
GalNAc through an α2,6 link. It has been 
recognized that circulating IgA1 from 
patients with IgAN displays an altered O-
glycan structure that may have a patho-
genic bearing on the development of IgAN. 
A reduced terminal Gal content in the 
O-glycans is found in IgA1 from patients 
with IgAN. Also, there is increased bind-
ing of GalNAc-specifi c lectins to serum 
IgA1, which suggests undergalactosylation 
of IgA1 hinge glycopeptides. A decrease 
in binding of IgA to Gal-specifi c lectins 
can result from the absence of Gal or the 
masking eff ect of NANA that is linked to 
Gal. Oligosaccharides in the hinge region 
normally carry negatively charged NANA, 
which is large and bulky compared with its 
protein backbone. Any change in the car-
bohydrate moiety aff ects the tertiary struc-
ture as well as the electrostatic charges that 
are pivotal in the interactions it exhibits 
and in its ability to recognize other mole-
cules such as the asialoglycoprotein recep-
tor and FcαRI. Th e NANA content in IgA1 
has been reported to be higher in patients 
with IgAN than in healthy control sub-
jects.1 IgAN patients also display increased 
levels of IgA glycoforms exposing NANA 
and GalNAc.2 Leung et al.3 found reduced 
terminal galactosylation in circulating 
monomeric IgA1 but not in pIgA1, which 
instead showed increased sialylation (α2,3 
linked to Gal). Th is abnormality of IgA1 
could have a bearing on the pathogenesis 
of IgAN, because the masking eff ect of 
NANA may hinder the clearance of pIgA1 
by the hepatic asialoglycoprotein receptor. 
An increase in its sialylated content would 
also render the pIgA from patients with 
IgAN more anionic. Th e totality of this 
evidence suggests that the Gal or perhaps 
the NANA content is ‘abnormal’ in O-gly-
cans of the IgA molecules in IgAN. As a 
consequence of this abnormality, there 
may be defective clearance of such abnor-
mal IgA from the circulation, resulting in 
a direct interaction of the abnormal IgA 
with glomerular mesangial cells.
Plasma IgA levels are determined by 
the rate of IgA production, uptake by leu-
kocytes, and removal by hepatocytes. In 
IgAN, FcαRI expression on leukocytes is 
increased, independently of plasma IgA 
levels, and FcαRI in leukocytes is not 
Circulating IgA is almost all produced in 
the bone marrow and consists of approxi-
mately 90% IgA1 and 10% IgA2, with a 
predominance of λ-light chain IgA of 
about 60%. It exists predominantly in the 
monomeric form (∼92%), with a small 
proportion as macromolecular IgA, con-
sisting of dimers and polymers. Dimeric 
IgA contains two monomeric IgA units 
joined by a bridging J chain. Th e precise 
composition of polymeric IgA (pIgA) is 
still unknown. Th e latter IgA complexes 
might be aggregates of IgA, IgA-containing 
immune complexes (ICs), or complexes 
of IgA associated with other proteins. IgA 
found in secretions, termed ‘secretory IgA’ 
(sIgA), is predominantly dimeric.
The human IgA1 isotype contains a 
unique hinge region between the CH1 
and CH2 domains of the α1 heavy chain. 
Th e hinge region has up to ten potential 
O-glycosylation sites, fi ve of which have 
been documented as ‘occupied.’ Th e fun-
damental structure of the O-glycans is the 
linkage between the α-anomeric carbon 
atom in N-acetylgalactosamine (GalNAc) 
and the hydroxy group of serine or threo-
nine (GalNAc-O-Ser or GalNAc-O-Th r). 
Th e GalNAc residue in the glycans of the 
human IgA1 hinge may be extended with 
β1,3-linked galactose (Galβ1,3GalNAc). 
Furthermore, sialic acid (N-acetyl-
neuraminic acid (NANA)) may bind to 
galactose (Gal) through an α2,3 link and to 
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saturated.4 Th e asialoglycoprotein recep-
tor of hepatocytes recognizes both ter-
minal Gal and the GalNAc residue of the 
IgA molecule. Defi ciency of Gal residues 
in the hinge region may profoundly aff ect 
the recognition of IgA1 by the hepatic 
asialoglycoprotein receptor and, hence, 
its catabolism. Th erefore, modifi cation of 
IgA’s carbohydrate structure can infl uence 
the direct interaction of IgA with mesang-
ial cells. Furthermore, leukocytes, hepato-
cytes, and mesangial cells bind to diff erent 
fractions of IgA, suggesting the presence of 
diff erent IgA receptors in these cells.
At least in part, mesangial IgA consists 
of macromolecular IgA. Th e fact that the 
J chain and free secretory component bind 
to IgA deposits supports the view that 
glomerular IgA in IgAN is mostly poly-
meric. Th e predominance of pIgA in the 
mesangium of IgAN is further supported 
by the detailed analysis of the kidney elu-
ates, eluated IgA being predominantly 
anionic.5 In another study,6 IgA1 pooled 
from 290 renal biopsy specimens with 
IgAN showed reduced O-glycosylation of 
glomerular IgA. In vitro studies revealed 
that binding of aggregated or polymeric 
IgA to mesangial cells in IgAN led to 
increased expression of nuclear factor-κB, 
c-Jun, interleukin-6, interleukin-8, mono-
cyte chemoattractant protein-1, tumor 
necrosis factor-α, and angiotensin II.7 
Recent studies also suggest that the patho-
physiological eff ects of IgA from patients 
with IgAN reside in a selected fraction 
of pIgA. Novak et al.8 showed decreased 
binding and internalization of IgA-ICs 
and IgA1-ICs containing IgG from IgAN 
patients by a hepatocyte cell line, presum-
ably because of the masking of the binding 
site in IgA1 glycans from the asialogly-
coprotein receptor. Inadequate hepatic 
catabolism may favor increased circulating 
IgA1-IgG-ICs and hence mesangial depo-
sition in IgAN patients. IgA-ICs containing 
aberrantly glycosylated IgA1 aff ect prolif-
eration of mesangial cells in vitro.9 Inter-
estingly, Gal-deficient pIgA1 myeloma 
protein bound better to mesangial cells in 
comparison with unmodifi ed myeloma-
derived pIgA1. However, circulating ICs 
containing aberrantly glycosylated IgA 
from patients with IgAN bound even bet-
ter, indicating that additional factors also 
have a role in the binding to mesangial 
cells. Leung et al.3 found that IgA-IgG-
ICs that bound mesangial cells were in the 
range of 280–900 kilodaltons with a major 
peak at 790 kilodaltons. Th e concentration 
of IgA-IgG-ICs in the macromolecular 
fractions was also higher in IgAN patients 
than in control subjects.
In this issue, Oortwijn et al.10 report the 
detection of circulating sIgA in patients 
with IgAN and healthy subjects. Th e serum 
concentration of sIgA represented 3% of 
the total pIgA. Th e high serum sIgA level 
was associated with hematuria. Isolated 
sIgA bound strongly to mesangial cells in 
vitro and stimulated cell proliferation and 
the production of interleukin-6. Impor-
tantly, the extent of sIgA accumulation in 
the eluate of glomeruli of a nephrectomy 
specimen with IgAN was high. Th e ques-
tion of whether sIgA is the pathogenic IgA 
responsible for IgAN still awaits resolution. 
A few issues must be clarifi ed before such 
speculation can be sustained. Th e glyco-
sylation or NANA profi le of eluated sIgA 
is unknown. Th e presence of glomerular 
sIgA deposits has never been documented 
in IgAN. Diff erential exposure of O- and 
N-glycans by the tetrameric conformation 
of sIgA is suggested by modeling studies. 
Delineating the binding mechanism of 
sIgA to mesangial cells remains diffi  cult, 
as such binding is not via the Fc fragment 
or secretory component. Th e electrostatic 
charge of ICs is important in the mesangial 
binding, and it has been documented that 
the binding of IgA to mesangial cells is 
charge-dependent.11 Th e pIgA with the 
highest net negative charge binds most 
to mesangial cells, and the binding can 
be altered by rendering the surface charge 
of the mesangial cells more anionic or 
cationic. The secretory component is 
heavily glycosylated. The contribution 
of glycosylation to mesangial binding 
remains unclear, as the charge on sIgA has 
not been well studied.
In the search for pathogenic IgA in IgAN, 
fundamental issues remain unresolved. 
What is the mechanism of mesangial 
binding? So far, no known IgA receptor 
has been found in mesangial cells. Will the 
nature of the pathogenic IgA aff ect the clin-
icopathological outcome of IgAN? A recent 
study suggests that the defi ciency of NANA 
of IgA1 (α2,6 linked to Gal) is associated 
with the pathological phenotype of IgAN.12 
Despite mesangial deposition, IgA deposits 
are not detected in the tubulointerstitium, 
yet tubular rather than mesangial pathol-
ogy provides a better index of prognosis. 
Mechanisms involved in the glomerulo-
tubular cross-talk, independent of tubular 
IgA deposition, have lately been discovered 
in IgAN.13 However, it is still unknown 
whether diff erent components of patho-
genic IgA aff ect the mediators involved 
in the cross-talk and lead to the diversity 
of renal survival and clinicopathological 
manifestations in IgAN. Further examina-
tion of these issues should provide addi-
tional insights into whether sIgA is the 
ultimate pathogenic IgA in IgAN.
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